Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Dementia01:30

Dementia

584
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
584
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

1.8K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.8K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

1.0K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.0K
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

2.1K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.1K
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

1.2K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Susceptibility to visual hallucinations in the amyotrophic lateral sclerosis-frontotemporal dementia spectrum: The role of dysfunctional attentional networks.

Cortex; a journal devoted to the study of the nervous system and behavior·2025
Same author

Fourteen years later: Reviewing the diagnostic criteria for behavioral-variant frontotemporal dementia.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025
Same author

Deciphering distinct genetic risk factors for FTLD-TDP pathological subtypes via whole-genome sequencing.

Nature communications·2025
Same author

Deciphering Distinct Genetic Risk Factors for FTLD-TDP Pathological Subtypes via Whole-Genome Sequencing.

medRxiv : the preprint server for health sciences·2024
Same author

Genome-wide analyses reveal a potential role for the MAPT, MOBP, and APOE loci in sporadic frontotemporal dementia.

American journal of human genetics·2024
Same author

An attentional and working memory theory of hallucination vulnerability in frontotemporal dementia.

Brain communications·2024
Same journal

Relationship between subjective well-being and cognitive performance in older adults.

Dementia & neuropsychologia·2026
Same journal

When exome analysis is the key for your patient with cognitive decline: a case report.

Dementia & neuropsychologia·2026
Same journal

Selective Kanji agraphia in crossed aphasia after right-hemisphere infarction: a case report.

Dementia & neuropsychologia·2026
Same journal

Global trends in Alzheimer's disease randomized controlled trials: a bibliometric analysis.

Dementia & neuropsychologia·2026
Same journal

Neuropsychiatric symptoms and social cognition in frontotemporal dementia and Alzheimer's disease.

Dementia & neuropsychologia·2026
Same journal

Mentes ativas (active minds): effects of a remote cognitive stimulation program.

Dementia & neuropsychologia·2026
See all related articles

Related Experiment Video

Updated: Feb 17, 2026

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains
12:28

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains

Published on: June 3, 2020

18.3K

Behavioural-variant frontotemporal dementia: an update.

Olivier Piguet1, John R Hodges1

  • 1Neuroscience Research Australia, Barker St, Randwick NSW 2031, Australia. School of Medical Sciences, the University of New South Wales, Sydney, Australia. ARC Centre of Excellence in Cognition and its Disorders, the University of New South Wales, Sydney, Australia.

Dementia & Neuropsychologia
|December 8, 2017
PubMed
Summary
This summary is machine-generated.

Behavioural-variant frontotemporal dementia (bvFTD) involves personality changes due to neural circuit disintegration. Early diagnosis using biomarkers, genetic testing, and neuroimaging is crucial for managing this heterogeneous neurodegenerative disease.

Keywords:
cognitionfrontotemporal dementiageneticsneuroimagingsocial cognition

More Related Videos

Operant Procedures for Assessing Behavioral Flexibility in Rats
08:30

Operant Procedures for Assessing Behavioral Flexibility in Rats

Published on: February 15, 2015

21.7K
Automated, Long-term Behavioral Assay for Cognitive Functions in Multiple Genetic Models of Alzheimer's Disease, Using IntelliCage
06:46

Automated, Long-term Behavioral Assay for Cognitive Functions in Multiple Genetic Models of Alzheimer's Disease, Using IntelliCage

Published on: August 4, 2018

12.8K

Related Experiment Videos

Last Updated: Feb 17, 2026

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains
12:28

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains

Published on: June 3, 2020

18.3K
Operant Procedures for Assessing Behavioral Flexibility in Rats
08:30

Operant Procedures for Assessing Behavioral Flexibility in Rats

Published on: February 15, 2015

21.7K
Automated, Long-term Behavioral Assay for Cognitive Functions in Multiple Genetic Models of Alzheimer's Disease, Using IntelliCage
06:46

Automated, Long-term Behavioral Assay for Cognitive Functions in Multiple Genetic Models of Alzheimer's Disease, Using IntelliCage

Published on: August 4, 2018

12.8K

Area of Science:

  • Neuroscience
  • Neurology
  • Genetics

Background:

  • Behavioural-variant frontotemporal dementia (bvFTD) presents with insidious personality and conduct changes, reflecting neural circuit degeneration impacting social cognition, emotion, motivation, and decision-making.
  • The pathology is diverse, involving tau, TDP-43, or FUS inclusions, with genetic mutations like C9orf72 accounting for 10-20% of cases.
  • Accurate in-life diagnosis is vital for developing targeted, disease-modifying therapies.

Purpose of the Study:

  • To review the diagnostic criteria and methods for behavioural-variant frontotemporal dementia.
  • To highlight the importance of biomarkers, genetic testing, and neuroimaging in improving diagnostic certainty.
  • To emphasize the role of caregiver support in managing bvFTD.

Main Methods:

  • Review of International Consensus Criteria for bvFTD diagnosis.
  • Emphasis on detailed clinical history from family members to identify behavioral features.
  • Integration of neuropsychological testing to assess cognitive and social processing deficits.
  • Role of brain imaging in enhancing diagnostic certainty.

Main Results:

  • The International Consensus Criteria define diagnostic certainty levels: possible, probable, and definite bvFTD.
  • Clinical history and neuropsychological testing are foundational for diagnosis.
  • Neuroimaging aids in increasing diagnostic confidence.
  • Biomarkers are increasingly important for pathological classification and treatment development.

Conclusions:

  • Accurate diagnosis of bvFTD relies on a combination of clinical assessment, neuropsychological testing, and neuroimaging.
  • Understanding the heterogeneous pathology and genetic underpinnings is key for future therapeutic strategies.
  • Comprehensive caregiver education and support are essential components of bvFTD management.